asthma

89,144 resultsPro users have access to +6390 Systematic Reviews

Filter Results
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
                    • Pro

                            Clinical Area Pro

                            Further Refinement
                            User Guide

                            User Guide

                            1
                            2024National Institute for Health and Care Excellence - Clinical Guidelines
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) NICE guideline Published: 27 November 2024 www.nice.org.uk/guidance/ng245 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guideline represent the view of NICE, arrived at after should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)(NG245)©
                            2
                            2024National Institute for Health and Care Excellence - Clinical Guidelines
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Asthma pathway (BTS, NICE, SIGN) Asthma pathway (BTS, NICE, SIGN) NICE guideline Published: 27 November 2024 www.nice.org.uk/guidance/ng244 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Asthma pathway (BTS, NICE, SIGN) (NG244)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2 of17 Contents Overview
                            Subscribe to Trip PRO for an enhanced experience
                            • Access to millions of Full-text articles where avaliable
                            • Unlock 100,000+ extra articles with Systematic Reviews
                            • Further Filtering Options
                            • No adverts
                            • Advanced Search Ability
                            • Enhanced SmartSearch showing unlimited related articles
                            Read more about Trip PRO
                            3
                            12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites Technology appraisal guidance Published: 5 March 2025 www.nice.org.uk/guidance/ta1045 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance represent health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dustmites (TA1045)© NICE 2025. All rights reserved. Subject to Notice
                            4
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Asthma - Scenario: Newly-diagnosed asthma and optimizing treatment Scenario: Newly-diagnosed asthma and optimizing treatment | Management | Asthma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Asthma 5. Management 6. Scenario: Newly-diagnosed asthma and optimizing treatment Asthma: Scenario: Newly-diagnosed asthma and optimising treatmentLast revised in January 2025 Covers the management of children and adults with newly diagnosed asthma and how to optimise treatment
                            5
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Asthma - Scenario: Follow-up of asthma Scenario: Follow-up of asthma | Management | Asthma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Asthma 5. Management 6. Scenario: Follow-up of asthma Asthma: Scenario: Follow-up of asthmaLast revised in January 2025 Covers the follow-up of children and adults with asthma in primary care. Scenario: Follow-up of asthma * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background
                            6
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Asthma - Scenario: Acute exacerbation of asthma Scenario: Acute exacerbation of asthma | Management | Asthma | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Asthma 5. Management 6. Scenario: Acute exacerbation of asthma Asthma: Scenario: Acute exacerbation of asthmaLast revised in January 2025 Covers the assessment and management of an acute exacerbation of asthma in primary care. Scenario: Acute exacerbation of asthma * Summary * Have I got the right topic? * How up-to-date
                            7
                            2024American Thoracic Society
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Research Priorities in Pediatric Asthma Morbidity: Addressing the Impacts of Systemic Racism on Children with Asthma in the United States. An Official American Thoracic Society Workshop Report In the United States, Black and Latino children with asthma are more likely than White to require emergency department visits or hospitalizations because of an exacerbation. Although many cite patient-level
                            8
                            2023NIHR HTA programme
                            Review Analysis
                            Appears Promising
                            ?
                            Digital interventions for hypertension and asthma to support patient self-management in primary care: the DIPSS research programme including two RCTs Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology AssessmentProgramme Grants for Applied ResearchPublic Health ResearchTwitterFacebookLinkedInEmailHome >> Journals >> Programme Grants for Applied Research >> Volume 10 >> Issue 11ToolkitDownload report PDFDownload report documentsDownload report XMLCitation ToolsPrintResponses to this report (0)Permissions informationVIEW PROJECTDigital interventions for hypertension and asthma to support patient self-management
                            9
                            2024BMJ Best Practice
                            Acute asthma exacerbation in children Skip to main contentSkip to searchLog inEnglish#{autosuggest.search}#{autosuggest.search}Acute asthma exacerbation in children MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:24 Dec 2023Last updated:17 Jan 2024SummaryAcute asthma exacerbations in children typically present with expiratory wheeze and a varying degree of respiratory corticosteroids and may require magnesium sulfate infusion, intravenous bronchodilators, and intramuscular adrenaline (if anaphylaxis is present).Severe and life-threatening exacerbations may require non-invasive ventilation or intubation. The intensive care team should be involved as early as possible.DefinitionAn asthma exacerbation is an acute or sub-acute episode of airflow obstruction occurring
                            10
                            Tezepelumab for treating severe asthma Tezepelumab for treating severe asthma Technology appraisal guidance Published: 20 April 2023 www.nice.org.uk/guidance/ta880 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tezepelumab for treating severe asthma (TA880)© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of28Contents 1 Recommendations
                            11
                            2024European Medicines Agency - EPARs
                            Omalizumab (Omlyclo) - treatment of severe persistent allergic asthma, severe chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic spontaneous urticaria (CSU) This site uses cookies. Visit our cookies policy page or click the link in any footer for more information and to change your preferences.Accept all cookiesAccept only essential cookiesSkip to main contentAn official EU websiteHow do you know?HomeMedicinesOmlycloOmlycloRSSShareOpinionEMA has issued an opinion on this medicineomalizumabMedicineHumanOverviewOn 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Omlyclo, intended for the treatment of severe persistent allergic asthma, severe chronic
                            12
                            Inpatient Management of Acute Asthma Exacerbation This is a CONTROLLED document for internal use only. Any documents appearing in paper form are not controlled and should be checked against the electronic SharePoint version prior to use. Document Scope: Hospital-wide Patient Care Document Type: Clinical Practice Guideline Approved on 2020-01-23 Next Review Date: 2023-01-22 Inpatient Management of Acute Asthma Exacerbation Version: 3 ©The Hospital for Sick Children ('SickKids'). All Rights Reserved. This document may be reproduced or used strictly for non-commercial clinical purposes. However, by permitting such use, SickKids does not grant any broader license or waive any of its exclusive rights under copyright or otherwise at law; in particular, this document may not be used
                            13
                            2024Prescrire
                            Tezepelumab (Tezspire) in severe asthma in adults and adolescents Prescrire IN ENGLISH - Spotlight ''Tezepelumab (Tezspire°) in severe asthma in adults and adolescents'', 1 May 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Tezepelumab (Tezspire°) in severe asthma in adults and adolescents SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives
                            14
                            2024Health Quality Ontario
                            Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment - PMC Back to Top Skip to main content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.Learn more: PMC Disclaimer| PMC Copyright Notice Ont Health Technol Assess Ser. 2024; 24(5): 1–225. Published online 2024 Jul 31. PMCID: PMC11423898PMID: 39329005Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health
                            15
                            2023BMJ Best Practice
                            Asthma in children Skip to main contentSkip to searchLog inEnglish#{autosuggest.search}#{autosuggest.search}Asthma in childrenVer contenido en español MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:8 Oct 2023Last updated:01 Nov 2023SummaryAs asthma in children differs from adult asthma, child-specific asthma guidelines should be used and adult and adolescent guidelines should not be extrapolated to younger age groups.The prevalence of childhood asthma appears to have plateaued in many affluent countries. However, asthma remains a significant cause of childhood morbidity and mortality, and is still a common problem managed in ambulatory and emergency care settings.Most children with asthma have mild intermittent asthma and do not require daily therapy. Minimum doses
                            16
                            2023BMJ Best Practice
                            Acute asthma exacerbation in adults Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageAcute asthma exacerbation in adults MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:6 Aug 2023Last updated:31 Aug 2023SummaryAn acute asthma exacerbation in adults presents as an acute or subacute episode of progressive worsening of asthma symptoms, such as shortness of breath, wheezing, cough, and chest tightness.Pulse rate, respiratory rate, subjective assessment of respiratory distress, accessory muscle use, and auscultation of the lung fields are key factors to assess during physical examination.An increase in airway obstruction that can be quantified objectively by peak flow measurement
                            17
                            2023BMJ Best Practice
                            Asthma in adults Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageAsthma in adults MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:23 Jul 2023Last updated:17 Aug 2023SummaryAsthma in adults presents with recurrent episodes of shortness of breath, chest tightness, wheezing , or coughing.Examination typically demonstrates an expiratory wheeze; however, in severe asthma there is poor air entry and the chest is silent.Treatment is stepwise, based on symptoms. Patients may need to monitor their peak expiratory flow daily and should be aware of the warning signs of a severe attack.Some patients may develop progressive, irreversible obstructive lung disease.DefinitionAsthma is a chronic
                            18
                            2023BMJ Best Practice
                            Occupational asthma Skip to main contentSkip to searchLog inEnglish#{autosuggest.search}#{autosuggest.search}Occupational asthma MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:15 Oct 2023Last updated:14 Nov 2023SummaryOccupational asthma should be suspected in all adult patients with asthma.An occupational history should be taken to identify work-related causes. Details of work exposures should be obtained from material safety data sheets and other material available to the patient from their workplace.Objective evidence of asthma should be obtained from spirometry, a bronchodilator response, and/or a methacholine challenge. Tests should be performed when the patient is symptomatic and/or within days of having exposure to a suspected aetiological agent.If sensitiser
                            19
                            2023Institute for Quality and Efficiency in Healthcare (IQWiG)
                            Review Analysis
                            Appears Promising
                            ?
                            Tezepelumab (severe asthma) ' Benefit assessment according to ' 35a SGB V 1 Translation of Sections I 1 to I 6 of the dossier assessment Tezepelumab (A sthma) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding . Tezepelumab (asthma) – Benefit assessment according to §35a SGB V1 EXTRACT Project: A22-122 Version: 1.1 Status: 6 April 2023 Extract of dossier assessment A22-122 Version 1.1 Tezepelumab ( asthma) 6 April 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Tezepelumab (asthma) – Benefit assessment
                            20
                            2024Saudi Clinical Guidelines
                            The Saudi initiative for asthma - 2024 update: Guidelines for the diagnosis and management of asthma in adults and children Skip to main contentAn official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationAs a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.Learn more: PMC Disclaimer | PMC Copyright NoticeAnn Thorac Med. 2024 Jan-Mar; 19(1): 1–55. Published online 2023 Dec 15. doi: 10.4103/atm.atm_248_23PMCID: PMC10911239PMID: 38444991The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and childrenMohamed Saad